Compare Marsh & McLennan Companies, Inc. (MRSH) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marsh & McLennan Companies, Inc. vs Viatris Inc — how do they compare? Marsh & McLennan Companies, Inc. trades at $176.13 (market cap $84.31B), while Viatris Inc trades at $17.58 (market cap $20.03B). The key difference: Marsh & McLennan Companies, Inc. is far larger — about 4.2× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.75%). Which is the better fit depends on your goals — on Pluang, investors hold Marsh & McLennan Companies, Inc. for 109 Days and Viatris Inc for 57 Days on average.
| MRSH | VTRS | |
|---|---|---|
Market Cap | $84.31B | $20.03B |
Volume | 3,948,947 | 14,109,977 |
Sector | Financials | Health |
52-Week High | $207.02 | $18.27 |
52-Week Low | $157.32 | $9.74 |
Typical Hold Time | 109 Days | 57 Days |
Enterprise Value | $104.99B | $32.15B |
Dividend Yield | 2.24% | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marsh (MRSH) trades at $173.66, up 1.11% today, with a bullish technical signal despite mixed moving averages and oscillators. The company shows strong fundamentals, with revenue growing to $26.98B in 2025 and net income of $4.16B, supported by consistent earnings beats. Recent news highlights the completion of the Accel Holdings acquisition, potentially enhancing its advisory services footprint. Valuation ratios include a P/E of 21.57 and ROE of 25.72%, indicating solid profitability.
The outlook for MRSH is positive, driven by earnings momentum and strategic acquisitions, but risks include high debt levels and competitive pressures. Analysts maintain a consensus price target of $202.71, suggesting upside potential, though the majority recommend Hold. Investors should weigh growth opportunities against execution risks and market volatility.
Viatris (VTRS) trades at $17.625, up 0.77% with a bullish technical signal. The company shows mixed fundamentals with declining revenue from $16.3B in 2022 to $14.3B in 2025 and negative net income margins, though recent quarters have beaten EPS estimates. Positive cash flow trends and a $0.12 dividend signal financial stability. Analyst consensus is mixed with 38% buy ratings and a $22.17 price target suggesting 26% upside.
The outlook balances operational strength against profitability challenges. Investment appeal lies in value metrics (P/S 1.38), consistent earnings beats, and dividend yield, but risks include sustained negative margins, high debt, and competitive pressures. The stock's re-rating depends on margin improvement and pipeline execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marsh & McLennan Companies, Inc.
Marsh & McLennan Companies Inc is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (management and economic consultancy).
Read more on MRSH →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
